Prana Biotechnology Limited (ADR) (NASDAQ:PRAN)

CAPS Rating: 1 out of 5

The Company develops therapeutic drugs designed to treat the underlying causes of degeneration of the brain and the eye as the aging process progresses, initially focusing on Alzheimer's disease.

Recs

0
Player Avatar pchop123 (76.51) Submitted: 9/20/2012 8:57:41 AM : Underperform Start Price: $2.68 PRAN Score: +14.16

the price just shot past reality & they are cash deficient to execute their business plan

Featured Broker Partners


Advertisement